Cathy Zhao, PhD

Effects of Aripiprazole Once-monthly (AOM) Across Manic Symptoms in Patients with Bipolar I Disorder (BP-I)

Background: The established role of oral aripiprazole in the treatment of Bipolar I disorder (BP-I) and the potential for a long-acting injectable formulation to improve adherence and pre...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019

Functioning in de novo and rollover patients with bipolar I disorder receiving aripiprazole once-monthly in a 52-week, open-label study

Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults...

Maxine Chen , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

10/08/2020

The Efficacy and Safety of Aripiprazole Once-Monthly 400mg (AOM 400) in African American/Black Patients Compared to Non-African American/Black Patients

Background: Recent analyses have indicated that medical treatment for schizophrenia varies among racial groups.

Jessica Madera , MD;

Stephen Murray , PharmD, MBA;

Maxine Chen , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Cathy Zhao , PhD;

11/22/2019

Efficacy and Safety of Aripiprazole Once-monthly in Patients With Relatively Rapid and Non-Rapid Cycling Bipolar I Disorder

Objective: To assess the efficacy and safety of Aripiprazole Once-Monthly (AOM 400) in preventing recurrence of mood episodes in patients with rapid and non-rapid cycling Bipolar I disord...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019